The Medical Letter on Drugs and Therapeutics
Ustekinumab (Stelara) for Crohn's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the human interleukin (IL)-12 and -23 antagonist ustekinumab (Stelara – Janssen Biotech) for treatment of moderately to severely active Crohn's disease in adults who were intolerant of or whose disease was unresponsive to treatment with immunomodulators or corticosteroids, or a tumor necrosis factor (TNF) inhibitor. Ustekinumab was approved earlier for treatment of psoriasis and psoriatic arthritis.1,2

STANDARD TREATMENT — Corticosteroids are used to induce remission of Crohn's disease. Azathioprine or 6-mercaptopurine (6-MP) can be used for maintenance of remission. A TNF inhibitor alone or in combination with azathioprine or 6-MP can be used for both induction and maintenance of remission in patients with moderate to severe disease.3 The integrin receptor antagonist vedolizumab (Entyvio) can be used ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ustekinumab (Stelara) for Crohn's Disease
Article code: 1511c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian